Skip to content
Clinical Trials – home

Universita' Degli Studi Di Verona

Verified siteinfo

Italy Piazzale Aristide Stefani 1, 37126 Verona, Italy

  • 107 trials recruiting
  • Non-small cell lung cancer · Cystic fibrosis · Obesity
  • Adults and children

About Specializations

Universita' Degli Studi Di Verona in Verona, Italy specialises in clinical trials of conditions such as Non-small cell lung cancer, Cystic fibrosis, Obesity, Acute lymphocytic leukaemia, and other specialisations. This site conducts important research.

Main research areas of the site

Neoplasms and Urologic Oncology

At the Universita' Degli Studi Di Verona, research in neoplasms focuses on cancers such as high-risk localized or locally advanced prostate cancer and acute lymphoblastic leukemia. These studies are designed to assess whether new treatment approaches can improve cancer control and long-term outcomes.

  • Evaluating treatment effectiveness in prostate cancer
  • Improving survival outcomes in infant acute lymphoblastic leukemia
  • Supporting better cancer care through new therapeutic strategies

This work reflects a strong clinical focus on testing therapies that may offer more effective options for patients with difficult-to-treat cancers.

Cardiovascular Diseases and Stroke Prevention

Clinical trials in cardiovascular diseases at this site are centered on reducing the risk of ischemic stroke after a recent event such as an acute stroke or high-risk transient ischemic attack. The main goal is to determine whether new antithrombotic treatments can better prevent future strokes while maintaining safety.

  • Preventing recurrent ischemic stroke
  • Studying treatment options after transient ischemic attack
  • Balancing effectiveness with bleeding risk

These studies aim to improve secondary prevention for people at elevated risk of another cerebrovascular event.

Eye Diseases and Pediatric Ophthalmic Care

Research in eye diseases includes studies involving children and adolescents who need ocular surface anesthesia for eye examinations. The purpose is to compare approaches that may make routine ophthalmic care more comfortable and effective for young patients.

  • Improving ocular anesthesia for pediatric eye exams
  • Supporting comfort during ophthalmic procedures
  • Evaluating practical options for everyday clinical use

This area highlights a patient-friendly focus on making pediatric eye care easier while maintaining clinical effectiveness.

Nutritional and Metabolic Diseases and Weight Management

Trials in nutritional and metabolic diseases at the Verona site address obesity and overweight in adolescents with related health conditions. The research is aimed at assessing whether new therapies can help improve weight control and associated health outcomes.

  • Managing obesity in adolescents
  • Addressing overweight with weight-related comorbidities
  • Testing treatments that may support healthier metabolic outcomes

These studies are part of a broader effort to find better options for young people affected by excess weight and its complications.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Piazzale Aristide Stefani 137126 VeronaItaly
Recruiting now
107 trials
Conditions studied
170
Partner status
Verified site

More sites in VeronaItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

238 clinical trials

Renal disorder

Recruiting

BI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
  • Sponsor:Boehringer Ingelheim Espana S.A.

A Phase III trial of BI 456906 weekly injections in adults with NASH and stage 2‑3 liver fibrosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH

Study of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Amgen Inc.

Bronchiectasis

Recruiting

Study of BI 1291583 tablets taken once daily for 76 weeks in adults with bronchiectasis

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:BI 1291583
  • Sponsor:Boehringer Ingelheim Espana S.A.

Obesity+1

Recruiting

Study on the Effectiveness and Safety of Orforglipron for Weight Management in Adolescents with Obesity or Overweight

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Sponsor:Eli Lilly & Co.

Study on the Safety of BHV-7000 for Adults with Hard-to-Treat Focal Onset Epilepsy

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Seagen Inc.

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab
  • Sponsor:CSL Behring LLC

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

A Study of Baricitinib to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

A Study of Baricitinib to Delay Type 1 Diabetes in Children and Adults at Risk of Developing the Disease

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

Phase 3 Study of Oral Orforglipron vs Weekly Dulaglutide in Children and Adolescents (10‑<18 years) with Type 2 Diabetes

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Dulaglutide
  • Sponsor:Eli Lilly & Co.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.